ACT IV: the final act for rindopepimut?
Mené dans 22 pays sur 745 patients atteints d'un glioblastome EGFRvIII positif, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du rindopépimut, un vaccin thérapeutique ciblant l'EGFR, à une chimiothérapie standard à base de
Glioblastoma remains an almost universally fatal cancer with few recent therapeutic advances. The gene encoding EGFR is the most frequently amplified gene in glioblastoma, with roughly 40% of primary glioblastomas showing EGFR amplification.1 Of these EGFR-amplified glioblastomas, 20–50% are characterised by a truncated gene resulting in the expression of mutated EGFRvIII, which is constitutively active. Activation of the EGFR pathway promotes several downstream pathways with oncogenic potential such as cellular proliferation and invasiveness.
The Lancet Oncology , commentaire, 2016